Prognostic factors for newly diagnosed prostate cancer and their role in treatment selection

Seminars in Radiation Oncology

Volumn 23, Issue 3, 2013, Pages 165-172

  Crook, Juanita ^a   Ots, Ana Fernandez ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYTOCHROME P450 3A4; PROTEIN P53; UVOMORULIN;

ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DISEASE SEVERITY; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; OVERALL SURVIVAL; PERINEURAL INVASION; PHASE 3 CLINICAL TRIAL (TOPIC); PLOIDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW (TOPIC);

ADENOCARCINOMA; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84878865937     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2013.01.002     Document Type: Review

References (52)

1. D'Amico A.V., Renshaw A.A., Sussman B., et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005, 294:440-447.
2. Mosse C.A., Magi-Galluzzi C., Tsuzuki T., et al. The prognostic significance of tertiary Gleason pattern 5 in radical prostatectomy specimens. Am J Surg Pathol 2004, 28:394-398.
3. Patel A.A., Chen M.H., Renshaw A.A., et al. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA 2007, 298:1533-1538.
4. Nanda A., Chen M.H., Renshaw A.A., et al. Gleason pattern 5 prostate cancer: Further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys 2009, 74:1419-1423.
5. Lotan Y., Shariat S.F., Khoddami S.M., et al. The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy. J Urol 2004, 171:2209-2214.
6. D'Amico A.V., Keshaviah A., Manola J., et al. Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2002, 53:581-587.
7. Harnden P., Shelley M.D., Clements H., et al. The prognostic significance of perineural invasion in prostatic cancer biopsies: A systematic review. Cancer 2007, 109:13-24.
8. Nguyen P.L., Chen M.H., Catalona W.J., et al. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys 2009, 73:659-664.
9. Sutcliffe P., Hummel S., Simpson E., et al. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: A systematic review. Health Technol Assess 2009, 13:1-219. iii, xi-xiii.
10. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24:1990-1996.
11. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487.
12. Zietman A.L., Bae K., Slater J.D., et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from proton radiation oncology group/American College of Radiology 95-09. J Clin Oncol 2010, 28:1106-1111.
13. Beckendorf V., Guerif S., Le Prisé E., et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011, 80:1056-1063.
14. Dearnaley D.P., Hall E., Lawrence D., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005, 92:488-498.
15. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
16. Crook J.M., Bahadur Y.A., Robertson S.J., et al. Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer 1997, 79:81-89.
17. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26:2497-2504.
18. D'Amico A.V., Chen M.H., Renshaw A.A., et al. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 2008, 299:289-295.
19. Denham J.W., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005, 6:841-850.
20. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285-1290.
21. Roach M., Bae K., Speight J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 2008, 26:585-591.
22. Bolla M., Van Tienhoven G., Warde P., et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-Year results of an EORTC randomised study. Lancet Oncol 2010, 11:1066-1073.
23. Crook J.M., Malone S., Perry G., et al. Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: Results from a Canadian randomized trial. Cancer 2009, 115:673-679.
24. Zelefsky M.J., Pei X., Chou J.F., et al. Dose escalation for prostate cancer radiotherapy: Predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 2011, 60:1133-1139.
25. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105.
26. Pahlajani N., Ruth K.J., Buyyounouski M.K., et al. Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:1949-1956.
27. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 2006, 64:527-533.
28. Crawford E.D., Grubb R., Black A., et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 2011, 29:355-361.
29. Albertsen P.C., Moore D.F., Shih W., et al. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011, 29:1335-1341.
30. Wilt T.J., Brawer M.K., Jones K.M., et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367:203-213.
31. Keating NL, O'Malley AJ, Freedland SJ, et al: Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol (in press).
32. Edge S.B., Byrd D.R., Compton C.C., et al. AJCC Cancer Staging Manual 2010, Springer, New York, NY. (ed 7).
33. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA 1999, 281:1598-1604.
34. Mohler J., Bahnson R.R., Boston B., et al. NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 2010, 8:162-200.
35. Memorial Sloan-Kettering Cancer Center Accessed August 15, 2012. http://nomograms.mskcc.org/Prostate/PreTreatment.aspx.
36. Vickers A.J., Savage C., O'Brien M.F., et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009, 27:398-403.
37. Stock R.G., Cesaretti J.A., Hall S.J., et al. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int 2009, 104:1631-1636.
38. Makarov D.V., Trock B.J., Humphreys E.B., et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007, 69:1095-1101.
39. Burdick M.J., Reddy C.A., Ulchaker J., et al. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer. Int J Radiat Oncol Biol Phys 2009, 73:1439-1445.
40. Khoddami S.M., Shariat S.F., Lotan Y., et al. Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy. BJU Int 2004, 94:42-46.
41. Epstein J.I., Allsbrook W.C., Amin M.B., et al. Update on the Gleason grading system for prostate cancer: Results of an international consensus conference of urologic pathologists. Adv Anat Pathol 2006, 13:57-59.
42. Feng F.Y., Qian Y., Stenmark M.H., et al. Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy. Int J Radiat Oncol Biol Phys 2011, 81:e361-e367.
43. Piña A.G., Crook J.M., Kwan P., et al. The impact of perineural invasion on biochemical outcome after permanent prostate iodine-125 brachytherapy. Brachytherapy 2010, 9:213-218.
44. Weight C.J., Ciezki J.P., Reddy C.A., et al. Perineural invasion on prostate needle biopsy does not predict biochemical failure following brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2006, 65:347-350.
45. Michalski J., Winter K., Roach M., et al. Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys 2012, 83:e363-e370.
46. Ho A.Y., Burri R.J., Cesaretti J.A., et al. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2009, 75:16-22.
47. Deutsch I., Zelefsky M.J., Zhang Z., et al. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy 2010, 9:313-318.
48. Martinez A.A., Gonzalez J., Ye H., et al. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011, 79:363-370.
49. Stock R.G., Yalamanchi S., Hall S.J., et al. Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation. J Urol 2010, 183:546-550.
50. Martinez A.A., Demanes D.J., Galalae R., et al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys 2005, 62:1322-1331.
51. Stock R.G., Ho A., Cesaretti J.A., et al. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int J Radiat Oncol Biol Phys 2006, 66:389-394.
52. Zelefsky M.J., Reuter V.E., Fuks Z., et al. Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 2008, 179:1368-1373. discussion 1373.